Advances in predictive biomarkers for immuno-oncology agents
Managing disease relapse in transplant patients with AML
Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy
Alan Burnett et al.
The IFM 2012-03 trial: what will the next step be?
Interim results of pegylated interferon alpha-2a for polycythemia vera and essential thrombocythemia